• RNV considers the study data to be material and likely to affect the price or value of its securities
• RNV did not present the study data, but an independent author presented it at the ACFAS conference
• RNV received the draft poster and abstract on March 22, 2025, but did not submit them as they were embargoed until the conference presentation

ReNerve Limited (RNV) has responded to an ASX Aware Letter regarding the release of new study data on its NervAlign Nerve Cuff product. RNV confirms the data is material and likely to have an effect on the price or value of its securities. RNV did not present the study data at the ACFAS conference, but rather the data was presented by one of the independent authors of the study, Dr. William Adams, at 8am Arizona time on March 27, 2025, which equates to 2am on March 28, 2025 AEST. RNV released its announcement regarding the data on the morning of March 28, 2025 pre-market open. RNV notes that the draft poster and abstract that were required to be submitted during October 2024 were not submitted by RNV, as they were submitted by Dr. Adams and his colleagues. RNV was aware the study was underway but had no knowledge of the data. RNV took the view that announcing the data prior to its presentation at the ACFAS conference could have jeopardized the study's acceptance, as conferences often reject presentations that have previously been released or presented. RNV confirms it is in compliance with the Listing Rules and its continuous disclosure obligations.